Rozenbaum Mark H, Judy Jen, Tran Diana, Yacisin Kari, Kurosky Samantha K, Begier Elizabeth
Pfizer bv, Capelle aan den IJssel, The Netherlands.
Pfizer Inc, New York, NY, USA.
Infect Dis Ther. 2023 Feb;12(2):677-685. doi: 10.1007/s40121-023-00758-5. Epub 2023 Jan 27.
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI)-related hospitalizations in older adults. Without RSV-specific treatment for adults, testing is uncommon, leading to potential underestimation of RSV incidence in real-world data studies. This study aimed to quantify the frequency of RSV testing during LRTI-related hospitalizations of older adults to inform interpretation of incidence estimates.
Administrative and billing data for hospitalizations of adults aged ≥ 65 years with a primary or secondary diagnosis of LRTI during the 2016-2019 RSV seasons (October-April) were extracted from the US all-payer Premier Healthcare Database (PHD). Billing codes identified RSV tests administered during eligible hospitalizations. The proportion of LRTI-related hospitalizations with a billed RSV test was calculated for each hospital in PHD, and summarized descriptively by hospital bed size, teaching status, and population served.
Most of the 937 study hospitals performed RSV testing infrequently during LRTI hospitalization; median percentage of LRTI hospitalizations with RSV testing was 4.3%, and 78.4% of hospitals performed RSV testing in less than 25% of LRTI-related hospitalizations. RSV testing varied extensively by hospital type. Median percentage tested was significantly higher for hospitals with ≥ 200 beds (9.1%) versus < 200 beds (1.6%), for teaching (11.0%) versus non-teaching (2.5%) hospitals, and in urban (7.4%) versus rural (0.7%) settings. The median percentage of RSV testing increased over time, from 0.8% to 6.3% between the 2016/17 and 2018/19 seasons.
A small proportion of older adults hospitalized with LRTI are tested for RSV in US hospitals. Large variability occurs across hospital types. Consequently, retrospective database analyses likely result in a substantial underestimation of the true RSV-related hospitalization incidence. RSV incidence studies using real-world data need to assess for RSV testing frequency and adjust their results for under ascertainment associated with limited testing.
呼吸道合胞病毒(RSV)是导致老年人下呼吸道感染(LRTI)相关住院的主要原因。由于缺乏针对成人的RSV特异性治疗方法,检测并不常见,这导致在真实世界数据研究中可能低估了RSV的发病率。本研究旨在量化老年人LRTI相关住院期间RSV检测的频率,以便为发病率估计的解释提供参考。
从美国全付费者Premier医疗数据库(PHD)中提取2016 - 2019年RSV流行季(10月至次年4月)期间年龄≥65岁、主要或次要诊断为LRTI的成人住院患者的行政和计费数据。计费代码确定了符合条件的住院期间进行的RSV检测。计算了PHD中每家医院LRTI相关住院且开具了RSV检测账单的比例,并按医院床位规模、教学状况和服务人群进行了描述性总结。
在937家研究医院中,大多数医院在LRTI住院期间很少进行RSV检测;LRTI住院患者中进行RSV检测的中位数百分比为4.3%,78.4%的医院在不到25%的LRTI相关住院患者中进行了RSV检测。RSV检测因医院类型而异。床位≥200张的医院检测的中位数百分比(9.1%)显著高于床位<200张的医院(1.6%),教学医院(11.0%)高于非教学医院(2.5%),城市地区(7.4%)高于农村地区(0.7%)。RSV检测的中位数百分比随时间增加,从2016/17季到2018/19季从0.8%增至6.3%。
在美国医院中,因LRTI住院的老年人中接受RSV检测的比例较小。不同医院类型之间存在很大差异。因此,回顾性数据库分析可能会大幅低估真正的RSV相关住院发病率。使用真实世界数据的RSV发病率研究需要评估RSV检测频率,并针对与有限检测相关的未充分确定情况调整其结果。